OncoMatch/Clinical Trials/NCT04657861
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Is NCT04657861 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies APRIL CAR-T cells for multiple myeloma in relapse.
Treatment: APRIL CAR-T cells — A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) positive expression
BCMA/TACI+ multiple myeloma (MM)
Required: TNFRSF13B positive expression
BCMA/TACI+ multiple myeloma (MM)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: relapsed after BCMA CAR-T therapy allowed
Previously treated with any CAR-T cell product or other genetically modified T cell therapies
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/L
Liver function
Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal
Cardiac function
Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L; Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify